ACM
VKTX icon

ACT Capital Management’s Viking Therapeutics VKTX Stock Holding History

ACT Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.16M Hold
209,300
– – 5.33% 7
2026
Q1 		$6.81M Buy
209,300
+3,200
+2% +$103K 5.35% 8
2025
Q4 		$7.25M Buy
+206,100
New +$7.3M 5.86% 6
2021
Q3 		– Sell
-128,500
Closed -$770K – 134
2021
Q2 		$770K Buy
+128,500
New +$763K 0.4% 49

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACT Capital Management's VKTX Position: Q2 2026 in Review

ACT Capital Management held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 209,300 shares worth $8.16M. The position accounts for 5.33% of the portfolio, ranked #7.

ACT Capital Management first reported a position in VKTX in Q2 2021 and has held it in 4 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • ACT Capital Management held 209,300 shares of Viking Therapeutics worth $8.16M as of Q2 2026.
  • ACT Capital Management left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 5.33% of ACT Capital Management's portfolio in Q2 2026, its #7 holding.
  • ACT Capital Management first reported a position in Viking Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.